| 
The Global Cardiovascular Innovation
Center (GCIC) is a $250 million research and product
development consortium established by the Cleveland
Clinic to significantly accelerate the commercialization
of cardiovascular products. Led by Steve Nissen, M.D,
the GCIC is enlisting a team of national leaders in
cardiovascular (CV) research, technology development,
and investing. Dr. Nissen is Chairman of the Cleveland
Clinic Department of Cardiovascular Medicine and the
outgoing President of American College of Cardiology.
The GCIC has been seeded with a $60 million grant from
the State of Ohio.
Our Mission
To be an international leader in developing, assessing,
acquiring, incubating and commercializing cardiovascular
products and companies by leveraging high value GCIC
services and clinical, research and commercialization
capabilities of member organizations.
GCIC Value Proposition
 The
GCIC will deliver new products, new companies and high
value services to its member companies and investors.
It will be headed by a cardiovascular industry leader
and its Board of Directors will include some of the
most prominent decision makers in the industry. Its
Commercial Advisory Board will include nationally recognized
venture investors, corporate executives and technologists.
Together they will set priorities and implement programs
that provide partners with a sustainable competitive
advantage.
The GCIC Accelerator will be a 60,000
sq ft new building housing selected GCIC member companies
located across from the heart of the Cleveland Clinic
research and clinical operations. The GCIC Accelerator
will incubate CV companies and provide high value proximity
to units of established companies.
The GCIC Accelerator will also feature
a 5,000 sq. ft. preclinical facility including surgical
rooms, preop and recovery rooms, and office facilities.
These preclinical facilities will be outfitted with
necessary testing equipment to facilitate all small-
and large-animal CV studies. Linkage with the Cleveland
Clinic’s cardiovascular ARO will ensure that translational
research moves rapidly from preclinical studies to early-
and late-phase clinical trials.
Why Focus on Cardiovascular Innovation?
Estimated at more than $420 billion in the US (CDC projection
for 2007), cardiovascular medicine is the largest market
opportunity within the $2.1 trillion U.S. healthcare
sector. CV is a ubiquitous disease burden and poses
clear challenges - medical, scientific and commercial
- with enormous benefits accruing to the investigators,
entrepreneurs and companies that produce enduring reductions
in morbidity and mortality. GCIC will build cross-industry
partnerships to leverage assets and expand resources,
facilitating the timely development and adoption of
new CV technology. GCIC partners are anticipated to
constitute a significant share of the top cardiovascular
companies when it is fully underway.
Partnership Opportunities
The GCIC will transform promising concepts into products
via spin-off companies, technology licenses, and equity
partnerships. Seed funding and partnerships for commercialization
will advance the technology and intellectual property
opportunities resulting from GCIC’s R&D projects.
We invite you to contact us and explore potential partnerships
that can help facilitate the development or expansion
of cardiovascular technologies.
Contact Us
Phone: 216-444-5322
Email: GCIC@ccf.org
Website: clevelandclinic.org/gcic
|
